Literature DB >> 19092107

Treatment effects for which shift or binary analyses are advantageous in acute stroke trials.

Jeffrey L Saver1, Jeffrey Gornbein.   

Abstract

BACKGROUND: In acute stroke trials, functional outcome may be analyzed by dichotomizing ordinal outcome scales or by evaluating the entire scale range (shift analysis). The conditions under which shift or binary analysis will be more efficient have not been previously well delineated.
METHODS: Model randomized clinical trials employing the modified Rankin Scale of global handicap were constructed to reflect 1) mild benefits experienced across all ranges of stroke severity (neuroprotective effect), 2) substantial benefits across all ranges of stroke severity (early recanalization effect), 3) substantial benefits across wide range of stroke severity but with limited ability to achieve fully normal outcome (late recanalization effect), 4) benefits clustered at unexpected health state transitions.
RESULTS: In neuroprotective models, shift analysis was the most efficient technique in detecting a treatment effect. In the early recanalization models, dichotomization at excellent outcome and shift analysis were of comparable efficiency, both superior to dichotomization at good outcome. In the late recanalization models, dichotomization at good outcome performed best, shift analysis less well, and dichotomization at excellent outcome poorly. In the unexpected benefits model, shift analysis substantially outperformed dichotomization analyses. These patterns held among the seven actual acute trials reporting full range Rankin outcomes and showing treatment benefit identified in the literature.
CONCLUSIONS: The pattern of treatment effect of the intervention determines whether shift analysis or simple dichotomized analysis will be more efficient. Shift analysis is especially advantageous when treatments confer a relatively uniform, mild benefit to patients over a wide range of stroke severities or confer benefits at unexpected but clinically important health state transitions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19092107      PMCID: PMC2677490          DOI: 10.1212/01.wnl.0000341308.73506.b7

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

Review 1.  Could stroke trials be missing important treatment effects?

Authors:  Eivind Berge; David Barer
Journal:  Cerebrovasc Dis       Date:  2002       Impact factor: 2.762

2.  Choice of test for comparing two groups, with particular application to skewed outcomes.

Authors:  Ian R White; Simon G Thompson
Journal:  Stat Med       Date:  2003-04-30       Impact factor: 2.373

3.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

4.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

5.  Erythropoietin therapy for acute stroke is both safe and beneficial.

Authors:  Hannelore Ehrenreich; Martin Hasselblatt; Christoph Dembowski; Lukas Cepek; Piotr Lewczuk; Michael Stiefel; Hans-Heino Rustenbeck; Norbert Breiter; Sonja Jacob; Friederike Knerlich; Matthias Bohn; Wolfgang Poser; Eckart Rüther; Michael Kochen; Olaf Gefeller; Christoph Gleiter; Thomas C Wessel; Marc De Ryck; Loretta Itri; Hilmar Prange; Anthony Cerami; Michael Brines; Anna-Leena Sirén
Journal:  Mol Med       Date:  2002-08       Impact factor: 6.354

6.  Use of the Barthel index and modified Rankin scale in acute stroke trials.

Authors:  G Sulter; C Steen; J De Keyser
Journal:  Stroke       Date:  1999-08       Impact factor: 7.914

7.  Bootstrap statistics of ECASS II data: just another post hoc analysis of a negative stroke trial?

Authors:  R Stingele; E Bluhmki; W Hacke
Journal:  Cerebrovasc Dis       Date:  2001       Impact factor: 2.762

8.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

9.  Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke.

Authors:  G P Samsa; D B Matchar; L Goldstein; A Bonito; P W Duncan; J Lipscomb; C Enarson; D Witter; P Venus; J E Paul; M Weinberger
Journal:  Am Heart J       Date:  1998-10       Impact factor: 4.749

10.  Sample size and power estimation for studies with health related quality of life outcomes: a comparison of four methods using the SF-36.

Authors:  Stephen J Walters
Journal:  Health Qual Life Outcomes       Date:  2004-05-25       Impact factor: 3.186

View more
  49 in total

Review 1.  Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases.

Authors:  Paul A Lapchak
Journal:  Expert Rev Med Devices       Date:  2012-01       Impact factor: 3.166

Review 2.  Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science.

Authors:  Paul A Lapchak
Journal:  Ann Med       Date:  2010-11-01       Impact factor: 4.709

Review 3.  Clinical trial design in the neurocritical care unit.

Authors:  C E Hall; M Mirski; Y Y Palesch; M N Diringer; A I Qureshi; C S Robertson; R Geocadin; C A C Wijman; P D Le Roux; Jose I Suarez
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

4.  Intra-arterial thrombectomy for acute ischaemic stroke patients with active cancer.

Authors:  Dongwhane Lee; Deok Hee Lee; Dae Chul Suh; Hyuk Sung Kwon; Da-Eun Jeong; Joong-Goo Kim; Ji-Sung Lee; Jong S Kim; Dong-Wha Kang; Sang-Beom Jeon; Eun-Jae Lee; Kyung Chul Noh; Sun U Kwon
Journal:  J Neurol       Date:  2019-06-07       Impact factor: 4.849

5.  Intravenous thrombolysis for ischemic stroke in the golden hour: propensity-matched analysis from the SITS-EAST registry.

Authors:  Georgios Tsivgoulis; Aristeidis H Katsanos; Pavla Kadlecová; Anna Czlonkowska; Adam Kobayashi; Miroslav Brozman; Viktor Švigelj; Laszlo Csiba; Klara Fekete; Janika Kõrv; Vida Demarin; Aleksandras Vilionskis; Dalius Jatuzis; Yakup Krespi; Chrissoula Liantinioti; Sotirios Giannopoulos; Robert Mikulik
Journal:  J Neurol       Date:  2017-03-18       Impact factor: 4.849

6.  Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke.

Authors:  D Sacks; B Baxter; B C V Campbell; J S Carpenter; C Cognard; D Dippel; M Eesa; U Fischer; K Hausegger; J A Hirsch; M S Hussain; O Jansen; M V Jayaraman; A A Khalessi; B W Kluck; S Lavine; P M Meyers; S Ramee; D A Rüfenacht; C M Schirmer; D Vorwerk
Journal:  AJNR Am J Neuroradiol       Date:  2018-05-17       Impact factor: 3.825

7.  Regression analysis of ordinal stroke clinical trial outcomes: an application to the NINDS t-PA trial.

Authors:  Stacia M Desantis; Christos Lazaridis; Yuko Palesch; Viswanathan Ramakrishnan
Journal:  Int J Stroke       Date:  2013-06-27       Impact factor: 5.266

8.  Impact of age and baseline NIHSS scores on clinical outcomes in the mechanical thrombectomy using solitaire FR in acute ischemic stroke study.

Authors:  M A Almekhlafi; A Davalos; A Bonafe; R Chapot; J Gralla; V M Pereira; M Goyal
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-20       Impact factor: 3.825

9.  Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy.

Authors:  Xianwei Wang; Xingquan Zhao; S Claiborne Johnston; Ying Xian; Bo Hu; Chunxue Wang; David Wang; Liping Liu; Hao Li; Jiming Fang; Xia Meng; Anxin Wang; Yongjun Wang; Yilong Wang
Journal:  Neurology       Date:  2015-07-17       Impact factor: 9.910

10.  Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA).

Authors:  Nishant Kumar Mishra; Stephen M Davis; Markku Kaste; Kennedy R Lees
Journal:  Diabetes Care       Date:  2010-09-15       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.